Conditioned place preference induced by a combination of L-Dopa and a COMT inhibitor, entacapone, in rats

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 1, 1998, Pages 23-26

  Katajamäki, Jaana ^a   Honkanen, Aapo ^a   Piepponen, T Petteri ^a   Lindén, Inge Britt ^b   Zharkovsky, Alexander ^c   Ahtee, Liisa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

Conditioned place preference; Dopamine 3 Methoxytyramine; Entacapone; L Dopa; Reinforcement

Indexed keywords

3 O METHYLDOPAMINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; ENTACAPONE; HOMOVANILLIC ACID; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC CORTEX; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CONDITIONING (PSYCHOLOGY); CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; ENZYME INHIBITORS; LEVODOPA; LIMBIC SYSTEM; MALE; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); SYNAPSES;

ANIMALIA;

EID: 0032078044     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00394-8     Document Type: Article

References (24)

1. Abercrombie E. D., Bonatz A. E., Zigmond M. J. Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525:1990;36-44.
2. Acquas E., Carboni E., de Ree R. H. A., Da Prada M., Di Chiara G. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J. Neurochem. 59:1992;326-330.
3. Andén N.-E., Grabowska-Andén M., Lindgren S., Thornström U. Synthesis rate of dopamine. Difference between corpus striatum and limbic system as a possible explanation of variations in reactions to drugs Naunyn Schmiedebergs Arch. Pharmacol. 323:1983;193-198.
4. Bunney B. S., Aghajanian G. K., Roth R. H. Comparison of effects of l-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. Nature. 245:1973;123-125.
5. Dworkin S. I., Goeders N. E., Smith J. E. The reinforcing and rate effects of intracranial dopamine administration. NIDA Res. Monogr. 67:1986;242-248.
6. El Gemayel G., Trouvin J. H., Prioux-Guyonneau M., Jacquot C., Cohen Y. Dopaminergic metabolism in various rat brain areas after l-dopa loading. J. Pharm. Pharmacol. 38:1986;691-694.
7. Hefti F., Melamed E., Wurtman R. J. The site of dopamine formation in rat striatum after l-dopa administration. J. Pharmacol. Exp. Ther. 217:1981;189-197.
8. Honkanen A., Piepponen T. P., Ahtee L. Morphine-stimulated metabolism of striatal and limbic dopamine is dissimilarly sensitized in rats upon withdrawal from chronic morphine treatment. Neurosci. Lett. 180:1994;199-222.
9. Kaakkola S., Wurtman R. J. Effects of COMT inhibitors on striatal dopamine metabolism. A microdialysis study Brain Res. 587:1992;241-249.
10. Kivastik T., Vuorikallas K., Piepponen T. P., Zharkovsky A., Ahtee L. Morphine and cocaine-induced conditioned place preference. Effects quinpirole and preclamol Pharmacol. Biochem. Behav. 54:1996;371-375.
11. Koob G. F. Drugs of abuse. Anatomy, pharmacology and function of reward pathways Trends Pharmacol. Sci. 13:1992;177-184.
12. Kuczcenski R., Segal D. S. Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J. Pharmacol. Exp. Ther. 262:1992;1085-1094.
13. Männistö P. T., Ulmanen I., Lundström K., Taskinen J., Tenhunen J., Tilgman C., Kaakkola S. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog. Drug. Res. 39:1992;291-350.
14. Melamed E., Hefti F., Wurtman R. J. Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism. Ann. Neurol. 8:1980;558-563.
15. Napolitano A., Zürcher G., Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of l-dopa and dopamine in rats. Eur. J. Pharmacol. 273:1995;215-221.
16. Nausieda P. A. Sinemet "abusers" Clin. Neuropharmacol. 8:1985;318-327.
17. Ng L. K. Y., Chase T. N., Coldburn R. W., Kopin I. J. l-dopa in parkinsonism. Neurology. 22:1972;688-695.
18. Nissinen E., Lindén I.-B., Schultz E., Pohto P. Biochemical and pharmacological properties of peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch. Pharmacol. 346:1992;262-266.
19. Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggen K., Carter J. H., Gancher S. T., Harmmerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 44:1994;913-919.
20. Priebe S. Levodopa dependence. A case report Pharmacopsychiatry. 17:1984;109-110.
21. Roth J. A. Membrane-bound catechol-O-methyltransferase. A reevaluation of its role in the O-methylation of catecholamine neurotransmitters Rev. Physiol. Biochem. Pharmacol. 120:1992;1-29.
22. Ruottinen H. M., Rinne U. K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J. Neurol. Neurosurg. Psychiatry. 60:1996;36-40.
23. Schechter M. D., Calcagnetti D. J. Trends in place preference conditioning with a cross-indexed bibliography; 1957-1991. Neurosci. Biobehav. Rev. 17:1993;21-41.
24. Wood P. L., Altar C. A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons. Utility of 3-methoxytyramine measurements Pharmacol. Rev. 40:1988;163-187.